Bio Capex To Revenue from 2010 to 2024

TECH Stock  USD 75.38  0.51  0.68%   
Bio Techne's Capex To Revenue is increasing with slightly volatile movements from year to year. Capex To Revenue is estimated to finish at 0.07 this year. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.05424827
Current Value
0.071
Quarterly Volatility
0.01693771
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bio Techne financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Techne's main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.3 M, Total Revenue of 1.2 B or Gross Profit of 808.2 M, as well as many indicators such as Price To Sales Ratio of 6.9, Dividend Yield of 0.0042 or PTB Ratio of 6.78. Bio financial statements analysis is a perfect complement when working with Bio Techne Valuation or Volatility modules.
  
Check out the analysis of Bio Techne Correlation against competitors.

Latest Bio Techne's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Bio Techne Corp over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Bio Techne's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Techne's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Bio Capex To Revenue Regression Statistics

Arithmetic Mean0.04
Geometric Mean0.04
Coefficient Of Variation39.35
Mean Deviation0.01
Median0.04
Standard Deviation0.02
Sample Variance0.0003
Range0.0532
R-Value0.41
Mean Square Error0.0003
R-Squared0.17
Significance0.13
Slope0
Total Sum of Squares0

Bio Capex To Revenue History

2024 0.071
2023 0.0542
2022 0.0336
2021 0.0406
2020 0.0476
2019 0.07
2018 0.0356

About Bio Techne Financial Statements

Investors use fundamental indicators, such as Bio Techne's Capex To Revenue, to determine how well the company is positioned to perform in the future. Although Bio Techne's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Capex To Revenue 0.05  0.07 

Currently Active Assets on Macroaxis

When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:
Check out the analysis of Bio Techne Correlation against competitors.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.32)
Dividend Share
0.32
Earnings Share
0.95
Revenue Per Share
7.424
Quarterly Revenue Growth
0.045
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.